Evidence map›Paper›PMID 40228486›Full record

ArticleActa haematologica2026

Streamline: Retrospective Cohort Study of FMS-Like Tyrosine Kinase 3-Mutated Acute Myeloid Leukemia - Real-World Treatment Patterns and Clinical Outcomes of Patients in First Relapse or Refractory Diagnosis.

Amer M Zeidan, Rebekah Yu, Yuexi Wang, Ziyu Lan, David L Grinblatt, Dina Elsouda, James Spalding, Alana Block, Maelys Touya, Mark S Walker and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta haematologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Amer M ZeidanDepartment of Hematology, Yale School of Medicine and Yale Cancer Center, New Haven, Connecticut, USA, amer.zeidan@yale.edu.
Rebekah YuReal World Evidence, ConcertAI, LLC, Cambridge, Massachusetts, USA.
Yuexi WangReal World Evidence, ConcertAI, LLC, Cambridge, Massachusetts, USA.
Ziyu LanReal World Evidence, ConcertAI, LLC, Cambridge, Massachusetts, USA.
David L GrinblattDepartment of Hematology, Endeavor Health Medical Group, Evanston, Illinois, USA.
Dina ElsoudaAstellas Pharma Global Development, Inc., Northbrook, Illinois, USA.
James SpaldingAstellas Pharma Global Development, Inc., Northbrook, Illinois, USA.
Alana BlockAstellas Pharma Global Development, Inc., Northbrook, Illinois, USA.
Maelys TouyaAstellas Pharma Global Development, Inc., Northbrook, Illinois, USA.
Mark S WalkerReal World Evidence, ConcertAI, LLC, Cambridge, Massachusetts, USA.
Bhavik J PandyaAstellas Pharma Global Development, Inc., Northbrook, Illinois, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

<p>Introduction: Recent advances in genomic research have expanded the treatment landscape for acute myeloid leukemia (AML). This study examined treatment patterns and clinical outcomes among relapsed/refractory (R/R) FMS-like tyrosine kinase 3 (FLT3)-mutated AML patients.

methodsThis retrospective longitudinal study included patients with confirmed AML diagnosis, FLT3 mutation, and 1st R/R event from 1/1/2015 to 1/31/2023 in the ConcertAI Oncology Dataset. Treatment patterns, FLT3 testing rates, real-world overall survival (rwOS), and real-world time to next treatment (rwTTNT) were studied.

resultsAmong the 336 treated patients, 50.6% received FLT3-tyrosine kinase inhibitors (FLT3-TKIs) as first treatment after R/R event, of which 51.8% received gilteritinib. High-intensity chemotherapy used as first treatment after R/R event decreased from 67.9% in 2015 to 20.0% in 2022, while FLT3-TKI utilization rose to 50% over the same period. Among the 246 patients tested for FLT3 at initial AML diagnosis, only 36% were retested at 1st R/R event. Median rwOS and rwTTNT among FLT3-TKI patients were 12.4 months and 2.9 months, respectively.

conclusionThis study reveals a trend toward increasing FLT3-TKI use and highlights the need for repeated FLT3 testing among R/R AML patients. Real-world evidence is vital in understanding R/R AML patient care amidst emerging therapies. </p>.

Indexed as

fms-Like Tyrosine Kinase 3Leukemia, Myeloid, AcuteMutationProtein Kinase InhibitorsAdultAgedAged, 80 and overDrug Resistance, NeoplasmFemaleHumansMaleMiddle AgedRecurrenceRetrospective StudiesTreatment OutcomeYoung AdultFLT3 protein, humanfms-Like Tyrosine Kinase 3Protein Kinase InhibitorsFLT3 testing ratesFMS-like tyrosine kinase 3-tyrosine kinase inhibitorReal-world overall survivalReal-world time to next treatmentTreatment durationTrend of treatment distribution

Identifiers

PMID40228486
PMCPMC12112888

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.